146 related articles for article (PubMed ID: 35625254)
1. Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease.
Chao CM; Lai CC; Lee CH; Tang HJ
Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625254
[TBL] [Abstract][Full Text] [Related]
2. Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis.
Lan SH; Chao CM; Chang SP; Lu LC; Lai CC
Surg Infect (Larchmt); 2021 Oct; 22(8):763-770. PubMed ID: 33625294
[No Abstract] [Full Text] [Related]
3. Characteristics and Influencing Factors of Coagulation Dysfunction Caused by Cefoperazone/Sulbactam.
Zeng J; Zou M; Min M; Xu M
Altern Ther Health Med; 2024 Jan; ():. PubMed ID: 38290444
[TBL] [Abstract][Full Text] [Related]
4. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
Suzuki K; Horiba M
Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
[TBL] [Abstract][Full Text] [Related]
5. Role of the gut microbiota in cefoperazone/sulbactam-induced epilepsy in mice with chronic renal failure.
Wu Y; Gu D; Li J; Li J; Hou G
Ren Fail; 2024 Dec; 46(2):2371551. PubMed ID: 38938213
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
Chen CH; Tu CY; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Lai CC
Infect Drug Resist; 2021; 14():2251-2258. PubMed ID: 34168466
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of efficacy between ceftriaxone and cefoperazone plus sulbactam in peri-operative treatment of acute suppurative cholangitis].
Zhou XS; Zou SQ; Dong JH; Wu WZ; Zhang YD; Zhang TL; Zeng Z; Li NF; Man GT
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1879-82. PubMed ID: 15631798
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
[TBL] [Abstract][Full Text] [Related]
9. Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.
Rho JP; Castle S; Smith K; Bawdon RE; Norman DC
J Antimicrob Chemother; 1992 Jun; 29(6):701-9. PubMed ID: 1506350
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
Muder RR; Agarwala S; Mirani A; Gayowski T; Venkataramanan R
J Clin Pharmacol; 2002 Jun; 42(6):644-50. PubMed ID: 12043952
[TBL] [Abstract][Full Text] [Related]
11. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Chen Y; Xiang Q; Liu L
J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
[TBL] [Abstract][Full Text] [Related]
13. Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study.
Zhang R; Gao L; Chen P; Liu W; Huang X; Li X
Front Pharmacol; 2023; 14():1170987. PubMed ID: 37361226
[No Abstract] [Full Text] [Related]
14. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
16. Effectiveness and Safety of Generic Formulation of Cefoperazone/Sulbactam (Bacticep®) in Treatment of Infections at Siriraj Hospital.
Koomanachai P; Tongsai S; Thamlikitkul V
J Med Assoc Thai; 2016 Jan; 99(1):8-14. PubMed ID: 27455819
[TBL] [Abstract][Full Text] [Related]
17. [Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections].
Beketov AS; Sidorenko SV; Pisarev VV; Komarov RM
Antibiot Khimioter; 2003; 48(3):34-41. PubMed ID: 12914120
[TBL] [Abstract][Full Text] [Related]
18. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
Gao C; Tong J; Yu K; Sun Z; An R; Du Z
Eur J Clin Pharmacol; 2016 Jul; 72(7):823-30. PubMed ID: 27023465
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of Coagulation Function in Patients Receiving Aspirin and Cefoperazone-Sulbactam With and Without Vitamin K
Wu S; Wu G; Wu H
Clin Ther; 2021 Dec; 43(12):e335-e345. PubMed ID: 34819242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
